Past Lectures

1) 1975 Genetics Colloquium, University of Michigan, Ann Arbor, MI

 

2) 1978 Biological Basis of Cancer Chemotherapy, Thessaloniki, Greece

 

3) 1980 Immunology Rounds, Johns Hopkins University/Good Samaritan Hospital, Bethesda

 

4) 1980 IXth Congress of the European Association of Poison Control Centers, Greece

 

5) 1981 Cystic Fibrosis Rounds, University of Florida, Gainesville

 

6) 1982 Health Care Delivery in Greece, New York

 

7) 1983 United Nations Environment Program - Mediterranean Action Plan, Athens

 

8) 1984 Gastroenterology Rounds, Boston University Medical Center, Boston

 

9) 1984 Ninth International Congress of Pharmacology, London

 

10) 1985 Immunotherapy of Cancer, Thessaloniki, Greece

 

11) 1986 Second World Conference on Inflammation, Monte Carlo

 

12) 1986 Conference on Healing, New York

 

13) 1986 Third E.N.T.- Neurosurgery Italian-Greek-Jugoslav Congress, Rome

 

14) 1986 National Conference on Cancer Treatment, Thessaloniki, Greece

 

15) 1987 World Conference on Analgesics, Caracas

 

16) 1987 Internal Medicine Association of Guatemala, Guatemala City

 

17) 1987 Neurology Grand Rounds, Social Security Administration of Mexico

 

18) 1987 Conference on Science and Religion, Boston

 

19) 1987 World Congress of Pediatrics, Panama

 

20) 1987 Fifth World Congress on Pain, Hamburg

 

21) 1987 35th Meeting of the European Tissue Culture Society, Patras, Greece

 

22) 1989 Third Interscience World Conference on Inflammation, Monte-Carlo

 

23) 1989 Fourth E.N.T. - Neurosurgery Italian-Greek-Jugoslav Congress, Greece

 

24) 1990 Annual Meeting, National Nutritional Foods Association, Boston

 

25) 1990 Panel speaker: 3rd ICA/NIH National Meeting on Interstitial Cystitis, New Orleans, LA

 

26) 1991 Sixth Panhellenic Congress of Otorhinolaryngology-Allergic Rhinitis, Thessaloniki

 

27) 1991 Panel Speaker: 4th ICA/NIH National Meeting on Interstitial Cystitis, Arlington, VA

 

28) 1992 First Panhellenic Congress of Allergy and Clinical Immunology, Athens

 

29) 1992 Pharmacology Program, Mt. Sinai School of Medicine, New York

 

30) 1992 Immunology Program, McMaster University, Canada

 

31) 1992 XI International Symposium on Infection and Allergy of the Nose, Rome

 

32) 1993 Fifth World Conference on Inflammation, Geneva

 

33) 1993 Keynote speaker: New trends in IC therapy, PA ICA Association, Harrisburg, PA

 

34) 1993 Keynote speaker: 7th NIH/ICA National Meeting, Orlando, FL.

 

35) 1993 Keynote speaker: Pathophysiology of interstitial cystitis: the role of the mast cells, First
International Seminar on Female Urology in Patras, Greece (November 19-21, 1993).

 

36) 1994 New Trends in the treatment of urticaria: neuroimmunoendocrine stimulation of skin mast cells.
Fourth International Symposium on Dermatology, Jeddah, Saudi Arabia (January 31-February 3, 1994).

 

37) 1994 Differentiation and pathophysiology of bone marrow-derived mast cells, Evangelismos General
Hospital, Athens, Greece (February 7, 1994).

 

38) 1994 Keynote speaker: The mast cell and inhibitors of its degranulation, Second Panhellenic Congress
of Allergy and Clinical Immunology in Athens, Greece (February 10-12, 1994).

 

39) 1994 Pathophysiology of neuroimmunoendocrine syndromes, AHEPA General Hospital, Thessaloniki,
Greece (February 14, 1994).

 

40) 1994 Inhibition of mast cell secretion by a unique phosphoprotein, Yale University School of Medicine
(May 20, 1994).

 

41) 1994 Keynote speaker: Scientific and social implications of generic drug use, Second Panhellenic
Congress of Hospital Pharmacists, Thessaloniki, Greece (May 27, 1994)

 

42) 1994 Keynote speaker: Politics and funding of drug development for orphan diseases, Seventh
Panhellenic Pharmaceutical Congress, Athens, Greece (June 11, 1994).

 

43) 1994 Keynote speaker: Neuroimmunoendocrin e involvement in interstitial cystitis. Tenth An annual
Meeting, Texas ICA, Houston, TX (November 5, 1994).

 

 

44) 1994 State of the Art Lecture: Pathophysiology and treatment of interstitial cystitis. C.E. Acken
International Meeting in Wuppertal-Barmen, West Germany (December 1, 1994).

 

45) 1995 Neuroimmunoendocrine stimulation of mast cells: new implications for pathophysiology and
therapy, Pulmonary and Critical Care Division, Tufts-New England Medical Center.

 

46) 1995 Plenary Lecture: Neurogenic inflammation and neuroinflammatory disorders. Sixth World
Conference on Inflammation, Geneva, (March 28, 1995).

 

47) 1995 Stress-induced skin mast cell activation. International Meeting on Mast Cell-Neuron Interactions,
Berlin (September 1995).

 

48) 1995 Pharmacology of interstitial cystitis: workshop. Eighth Annual ICA Meeting, San Diego (October
1995).

49) 1996 The mast cell: a neuroimmunoendocrine master player. 2nd European Medical Students'
Symposium, Thessaloniki, Greece (May 4-5, 1996).

 

50) 1996 New trends explaining the pathophysiology of allergy: correlation with neuroinflammatory
syndromes. Pan Cretan Medical Congress, Heraklion, Greece (October 24-27, 1996).

 

51) 1996 Neuroimmunoendocrine basis of interstitial cystitis. 3rd International Society for
Neuroimmunomodulation, Bethesda MD (November 13-15, 1996).

 

52) 1996 Pathophysiology of migraines and the role of stress. First Pain Congress of the Hellenic Pain
Society, Volos, Greece (December 1-3, 1996).

 

53) 1997 Urocortin-induced skin mast cell activation and vasodilation: implications for the role of stress in
atopic diseases. Section of Allergy and Clinical Immunology, Yale University School of Medicine, New
Haven, CT (March 7, 1997).

 

54) 1997 A natural phosphoprotein inhibiting mast cell secretion: implications for the therapy of atopic
diseases. Annual Congress of the European Association of Allergy and Clinical Immunology, Rhodes,
Greece (June 1-5, 1997).

 

55) 1997 Urocortin and CRF trigger mast cell activation and increased vascular permeability: implications
for the pathophysiology of stress-induced atopic and inflammatory syndromes. Seventh Interscience World
Conference on Inflammation, Geneva (May 19-21, 1997).

 

56) 1997 Chairman, Round table discussion on post graduate medical education. Third European Medical
Student Congress, Crete, Greece (April 11-13, 1997).

 

57) 1997 Chairman, Symposium on Immune-Neuronal-Endocrine Interactions in the Pathophysiology of
Allergic and Autoimmune Diseases. Annual Congress of the European Association of Allergy and Clinical
Immunology, Rhodes, Greece (June 1-5, 1997).

 

58) 1997 Grand Rounds. Interstitial Cystitis and Pelvic Pain. Department of Obstetrics and Gynecology,
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (October 9, 1997).

 

59) 1997 Pharmacology and Interstitial Cystitis. Interstitial Cystitis Association's Ninth Annual Meeting,
Arlington, VA (November 1 & 2, 1997).

 

60) 1997 CRH-Induced Vascular Permeability and Its Role in Stress-Induced Syndromes. University of
Pennsylvania Medical Center (November 5, 1997).

 

61) 1998 Allergy and mast cell mediators in cyclic vomiting. 2nd International Scientific Symposium on
Cyclic Vomiting Syndrome, Milwaukee, WI (April 24-25, 1998).

 

62) 1998 Psychological stress triggers cardiac mast cell activation and myocardial ischemia in mice. XVI
World Congress of the International Society for Heart Research, Rhodes (May 30, 1998).

 

63) 1998 Sex Differences in Pain Perception in Neuroinflammatory Syndromes. 5th Congress of the Hellenic
Anesthesiology and Intensive Care Medicine Society, Thessaloniki (June 5, 1998).

 

64) 1998 Pharmacokinetics and polypharmacy in the elderly. The problem of benzodiazepines. 5th Congress
of the Hellenic Anesthesiology and Intensive Care Medicine Society, Thessaloniki (June 5, 1998).

 

65) 1998 Health Care Opportunities in the Private Sector. Prospects and Challenges for the Greek and
International Health Care Sector of Today and Tomorrow. The Economist Conferences, Athens (November
11-12, 1998).

 

66) 1998 Corticotropin releasing hormone and mast cells: a new view of neurogenic inflammation.
Endocrinology Grand Rounds, New England Medical Center (Nov 24).

67) 1999 Biomedical research and health as stabilizing factors among world communities. Key Note
Address: Fifth World Hellenic Biomedical Conference, New York City (December 4-6, 1998).

 

68) 1999 Novel approaches to pain: gender, sex and neurogenic inflammation. HIT: Hellenic-Israeli-Turkish
Conference on Pain, Crete (May 1999).

 

69) 1999 Effect of acute stress on inflammatory processes. European Conference on Biomedical Research
and Peace, Cyprus (October 17-21, 1999).

 

70) 2000 Pathophysiology and treatment of neuro-inflammatory syndromes. First Congress of the Hellenic
Pharmacological Society, Athens (February 19, 2000).

 

 

71) 2000 The use and abuse of ethical medications: the next millennium. The Economist Conferences,
Athens (June 10, 2000).

 

72) 2000 Translational Research: a case study. First Conference on Biomedical Research in Education,
Heraklion, Greece (October 6-8, 2000).

 

73) 2000 Acute stress induces cardiac IL-6 release and inflammation: therapeutic effect of natural
flavonoids. Sixth Conference of the World Hellenic Biomedical Association, Athens, Greece (October 11-
14, 2000).

 

74) 2001 Benefits and risks of epharma. European Conference on Health, Thessaloniki, Greece (March 8,
2001).

 

75) 2001 Structural requirements for anti-inflammatory effects of flavonoids. Advanced Medicinal
Chemistry Seminars, Thessaloniki, Greece (May 18, 2001).

 

76) 2001 Design and implementation of an electronic drug interactions program for Greece: why it is
needed and why it is not in place. The First Flessas Memorial Lecture. The Hellenic Medical Society of
New York and Hellenic Link, Inc. , New York City (June 10, 2001).

 

77) 2001 Stress-induced inflammation: asthma, migraines, multiple sclerosis and beyond. Plenary Lecture,
National Minority research Symposium, Cancun, Mexico (October 18-20, 2001).

 

78) 2002 Acute stress-induced blood-brain-barrier permeability, a mast cell and corticotropin releasing
hormone dependent process. Division of Rheumatology, Immunology and Allergy, Brigham and Women's
Hospital, Harvard Medical School (March 25, 2002).

 

79) 2002 Selective release of IL-6 from human mast cells. Keynote speaker. 8th Annual Meeting, The
Mastocytosis Society, Windsor Locks, CT (October 4&5, 2002).

 

80) 200 2 The role of mast cells in the neurocutaneous axis. 1st International Workshop on cutaneous
neuroendocrinology, Hamburg, Germany (Sept. 13-15, 2002).

 

81) 2002 Dietary supplement effect on mast cells. International Symposium on Complementary Alternative
Medicine - Allergy, Asthma & Immunology, American College of Allergy, Asthma and Immunology, San
Antonio, TX (Nov, 14, 2002).

 

82) 2003 Mast cells in inflammatory arthritis. Department of Biochemistry, Tufts University School of
Medicine. Boston, MA (January 9, 2003).

 

83) 2002 Abuse of OTC drugs. Brookline High School, Brookline, MA. (December 2002 series).

 

84) 2003 Abuse of dietary supplements. Brookline High School, Brookline, MA (January 2003 series).

 

85) 2003 Stress induced-bladder inflammation. International IC Conference, Kyoto, Japan (March 28 – 30,
2003).

 

86) 2003 Global health, leadership and world peace. Keynote Address at 10th Annual Conference of the
Midwest Institute, Cleveland, OH (April 5, 2003).

87) 2003 Code 99: Cardiac mast cells feel the squeeze. Department of Medicine, Tufts - New England
Medical Center (April 8, 2003).

 

88) 2003 Global education and world leadership. Keynote address, St. Louis Community College, St.
Louis, MO (August 25, 2003).

 

89) 2004 The mast cell as an immune sensor of stress. Dept. Of veterinary PathoBiology, College of
veterinary Medicine, University of Minnesota, St. Paul, MN (April 28, 2004).

 

90) 2004 Co-Chairman, Emerging Infectious Diseases and New Problems, 3rd International Workshop on
Immunology and Infectious Diseases, Naples, Italy (June 8-10, 2004).

 

91) 2004 Corticotropin-releasing factor-mast cell axis: Link to allergic diseases. Stress and Asthma,
Arlington, VA (October 2, 2004).

 

92) 2004 Stem cell physiology/The role of mast cells. 6th International Cord Blood Society Congress,
Boston, MA (October 3, 2004).

 

93) 2004 Mast cells as key modulators of environmental and psychological stress. 3rd International
Conference on Innate Immunity, Hersonisos, Crete, Greece (October 11, 2004).

 

94) 2004 Acute stress triggers selective mast cell activation through CRH and IL-1. Gastroenterology
Division, Beth Israel/Deaconess Medical Center-Harvard Medical School, Boston, MA (October 27, 2004).

 

95) 2004 Selective mast cell activation mediates the effect of acute stress. The Mind/Body Medical Institute-
Harvard Medical School, Boston, MA (November 22, 2004).

 

96) 2005 Activation of distinct CRH receptors leads to selective secretion of either IL-6 or VEGF from
human mast cells. 5th Mast Cell Workshop: Mast Cell Signaling and Function in Health and Disease, Eilat,
Israel (February 6-10, 2005).

 

97) 2005 Stress, mast cells and CR: The fateful triangle of inflammatory diseases. 39th Annual Scientific
Meeting of the European Society for Clinical Investigation, Athens, Greece (April 9, 2005).

 

98) 2005 Critical role of mast cells in stress-induced inflammatory disorders. 6th Meeting of the
International Society for NeuroImmunomodulation. Athens, Greece (September 25-28, 2005).

 

99) 2005 Neuroimmune aspects of painful bladder syndrome/interstitial cystitis and endometriosis: two
major chronic pelvic pain disorders. 6th Congress on Women's health & Disease. Athens, Greece
(September 25-28, 2005).

 

100) 2005 Critical role of mast cells and neuropsychiatric disorders. Annual Meeting of the Systemic
Mastocytosis Society, Santa Ana, CA (October 7-10, 2005).

 

101) 2005 Mast cells in chronic fatigue syndrome and fibromyalgia. Munich, Germany (November 28,
2005).

 

 

102) 2006 Role of mast cells in inflammatory disorders. 10th Medical Meeting of the Naval Hospital, Athens,
Greece (February 10-11, 2006).

 

103) 2006 Migraine headaches: the immunologist's view. Cardiology Update 2006- Cardiology & Neurology
at a Crossroad, Athens, Greece (April 14-15, 2006).

 

104) 2006 The role of mast cells in acute coronary syndromes. Cardiology Update 2006-Coronary Artery
Disease Prevention & Therapy Update, Athens, Greece (April 14-15, 2006).

 

105) 2006 Stress-induced skin mast cell activation and increased vascular permeability. Conference on Stress
and skin, New York, NY (June 2-5, 2006).
89

 

106) 2006 Stress, mast cells and the blood-brain-barriers: the fateful triangle in MS pathogenesis. Serono
Pharmaceutical, Geneva, Switzerland (June 16, 2006).

 

107) 2006 The immune sensor of environmental stress. Hellenic Armed Forces Medical Symposium,
Thessaloniki, Greece (Nov. 25, 2006).

 

108) 2007 The spectrum of mastocytosis. University of Carolina College of Pharmacy, Columbia, SC
(January 23, 2007).

 

109) 2007 Mastocytosis and mast cell activation diseases. Hellenic Hematology Association, Athens, Greece
(Feb. 3, 2007).

 

110) 2007 The effect of stress on inflammatory diseases. Open Public University and Hellenic Medical
Society, Municipality of Hania, Crete, Greece (Feb. 21, 2007).

 

111) 2007 Skin corticotropin-releasing hormone receptor expression in urticaria, psoriasis and mastocytosisimplications
for multiple sclerosis. Section of Allergy and Clinical Immunology, Yale University School of
Medicine, New Haven, CT (March 9, 2007).

 

112) 2007 Mast cell-dependent T cell stimulation and inhibition by luteolin. Section of Allergy and Clinical
Immunology, Yale University School of Medicine, New Haven, CT (March 9, 2007).

 

113) 2007 Kounis syndrome. In: Drug-Eluting Stents: Thrombosis and Hypersensitivity. 56th Annual
Scientific Session, Am. College of Cardiology (March 24-27, 2007; New Orleans, LO).

 

114) 2007 CRH, mast cells and bladder function. HANS SELYE and Saint Justine Hospital Centennial
Symposium: Stress: basic Mechanisms and Clinical Implications (July 11-14, 2007, UNIVERSITÉ
DU QUÉBEC À MONTRÉAL (UQAM), Montreal, Qubec, Canada).

 

115) 2007 Mast cells, T cells and inhibition by luteolin: Implications for the pathogenesis and treatment of
multiple sclerosis. 2nd International Immune Mediated Diseases Congress (September 10-14, Moskow,
Russia).

 

116) 2007 Selective release of mast cell mediators. Department of Pathology, Boston University (October 2,
2007).

 

117) 2007 Selective mediator release and effect of stress in urticaria pigmentosa. Annual Meeting, US
Systemic Mastocytosis Society (October 12, 2007; Houston, TX).

 

118) 2007 CRH dysregulation in psoriasis. 3rd Attikes Dermatology Days Congress (November 5, 2007;
Athens, Greece).

 

119) 2007 Regulation of selective release of mast cell mediators. Brigham and Women's Hospital-Dana
Farber Cancer Center, Harvard University (November 29, 2007; Boston, MA).

 

120) 2007 Role of mast cells in wound healing. 8th Annual Meeting on Wound Healing-Science and
Industry-CME lecture (St. Thomas, USA; December 14, 2007).

 

121) 2008 Interstitial Cystitis/Painful Bladder Syndrome. University of Phoenix, (January 1, 2008;
Phoenix, AZ).

 

122) 2008 Mast cells, myelin basic protein and substance P enhance T cell activation: inhibition by luteolin
and implications for multiple sclerosis. International Conference on Neural Signaling (Feb. 16-20,
2008; Pacific Grove, CA).

 

123) 2008 Interstitial Cystitis: Bladder Pain and Beyond. Lakeland Medica Center-CME lecture, (March
20, 2008; St. Joseph, MI).

 

124) 2008 Mast cells, myelin basic protein and substance P enhance T cell activation: and multiple sclerosis.
Department of Immunology, University of Connecticut (April 17, 2008; Farmington, CT).
90

 

125) 2008 Chair, Round Table Discussion on pharmacology teaching. 5th Panhellenic Congress of
Pharmacology (May 23-25, 2008; Athens, Greece).

 

126) 2008 Rupatadine inhibits mediator secretion from human mast cells. XXVII Congress of the European
Academy of Allergology and Clinical Immunology (June 7-11, 2008; Barcelona, Spain).

 

127) 2008 Human mast cells stimulate activated T cells, an effect increased by substance P and inhibited by
the flavonoid luteolin. XXVII Congress of the European Academy of Allergology and Clinical Immunology
(June 7-11, 2008; Barcelona, Spain).

 

 

128) 2008 Mast cell-T cell interactions in health and disease. 5th International Innate Immunity Conference
(June 21-26, 2008; Hania, Greece).

 

129) 2008 Role of mast cells in cancer growth. 3rd PanHellenic Forum on Oncology (July 6-7, 2008; Hania,
Greece).

 

130) 2008 Novel therapeutic targets for autism. Defeat Autism Now (October 24-26, 2008; San Diego, CA).

 

131) 2008 New aspects of regulation of mast cell activation. 5th Balkan Congress of Alleregology and
Clinical Immunology October 17-19, 2008; Thessaloniki, Greece).

 

132) 2008 Autism, food intolerance and mast cells. 5th Balkan Congress of Alleregology and Clinical
Immunology October 17-19, 2008; Thessaloniki, Greece).

 

133) 2008 Neuropeptide interactions in skin inflammation. Attica Dermatologic Days IV (November 21-23,
2008; Athens, Greece).

 

134) 2008 Role of mast cells in mesenteric traction syndrome. T-NEMC Anesthesia Grand Rounds (Dec. 8,
2008).

 

135) 2009 Perinatal mast cell activation and risk of autism. Yale University Allergy and Clinical
Immunology Grand Rounds (February 9, 2009; New Haven, CT).

 

136) 2009 Mast cells disrupt the gut-blood-brain barriers and contribute to autism. Autism One 2009
Conference (Chicago, IL; May 22-24, 2009).

 

137) 2009 Rupatadine: mechanism of action and anti-inflammatory effects. Why multiple actions? The
Pharmacologist's point of view. II Multidisciplinary Symposium. (Guatemala; May 29, 2009).

 

138) 2009 Novel antihistamines: Dual anti-mediator action and anti-inflammatory effects. XIX World
Congress of Oto-Rhino-Laryngology (São Paulo, Brazil; June 3, 2009).

 

139) 2009 Role of mast cells in blood-brain-barrier permeability and autism. Autism 1 Conference (Chicago,
IL; May 22, 2009).

 

140) 2009. Mastocytosis, allergic symptomatology and autism. National Autism Association (Fort Lauderdale,
FL; Nov. 12, 2009).

 

141) 2009 IL-33 augments substance P-induced VEGF release from human mast cells and its expression is
increased in psoriasis. Attica Dermatologic Days V (November 25, 2009; Athens, Greece).

 

142) 2009 Anti-inflammatory effects of rupatadine. Regional Allergy Update (Nicosia, Cyprus; Dec.7, 2009).

 

143) 2009 Anti-inflammatory actions of newer anti-histamines. (Berlin, Germany; Dec. 17, 2009).

 

144) 2010 Mast cells and mitochondria: culprits in the pathogenesis of allergy. PanHellenic Allergy
Conference (Athens, Greece; April 17, 2010).

145) 2010 "Allergic-like" symptoms, brain inflammation and autism: beneficial effect of a luteolin
formulation (NeuroProtek)." Autism 1 Conference (Chicago, IL; May 28, 2010).

 

146) 2010 "Mast cells and mitochondria-culprits in the pathogenesis of autism: novel treatment."
National Autism Association Conference (Tampa, FL; November 12, 2010).

 

147) 2010 "Mast cells and mitochondria: culprits in inflammation and auto-immunity" UCLA. (Los Angeles:
December 13, 2010).

 

148) 2010 "Mast cells: multitasking at the edge of wounds." Wound Healing Conference (St. Thomas;
December 10, 2010).

 

149) 2011 "The role of IL-9 and IL-33 in mast cell activation." Brigham & Women's Hospital-Harvard
Medical School. (Boston, MA; February 8, 2011).

 

150) 2011 "Neuroinflammation and disruption of the gut-blood-brain barriers-benefits of NeuroProtek ."
Autism One (The Westin Hotel, Lombard, IL; May 26, 2011)

 

151) 2011 ''Neurotensin and extracellular mitochondrial DNA as potential biomarkers and novel treatment
targets.'' (The Westin Hotel, Lombard, IL; May 26, 2011)

 

152) 2011 ''Aberrant inflammatory response in autism-Mast cell activation and the latest research in novel
biomarkers and treatment directions''. International Autism Biomedical Conference ( Queen Mary
University of London' June 18-19, 2011)

 

153) 2011 ''Neurotensin and extracellular mitochondrial DNA as potential biomarkers and novel treatment
targets..'' New York Metro Chapter –National Autism Association (New York, NY; September 8, 2011)

 

153) 2011 "Neuroinflammation and disruption of the gut-blood-brain barriers-benefits of NeuroProtek ."
New York Metro Chapter –National Autism Association (Westchester, NY; September 9, 2011)

 

154) 2011 'Neurotensin and extracellular mitochondrial DNA as potential biomarkers and novel treatment
targets.'' Autism Canada Foundation- Changing the course of autism conference. (Kitchener/Waterloo,
Canada; October 14, 2011)

 

 

155) 2011 ''Role of Mast cells in blood-brain-barrier permeability and beneficial effect of select flavonoids.''
Interscience Conference on Multiple Sclerosis (Athens Greece; October 1 2011)

 

156) 2011 "Mast cells and mitochondria: culprits in the pathogenesis of inflammatory skin diseases." Second
Seminar in Dermatology Research ( Heraklion, Crete; October 1 2011)

 

157) 2011 "Neurotensin and extracellular mitochondrial DNA as potential biomarkers and novel treatment
targets.'' Autism One/Spectrum Possibilities (St. Michael, Barbados; November 5 2011)

 

158) 2011 ''Increased oxidative stress and immune dysregulation in Autism Spectrum Disorders.'' National
Autism Conference (St. Pete Beach, FL; November 13 2011)

 

159) 2012 "Comparison of Cromolyn, Quercetin and Luteolin in Human Mast Cell Inhibition." Regional
Mastocytosis Conference (National Jewish Health Main Campus, Denver, CO; May 5th, 2012).

 

160) 2012 "Novel Treatment Approaches for Autism." The Massachusetts Chapter of TACA.org (Talk About
Autism Now, Wrentham Senior Center, Wrentham, MA ; May 8, 2012).

 

161) 2012 "Can we block mast cell activation?" Regional Mastocytosis Conference (Edwardsville Library,
Edwardsville, IL; May 5, 2012).

162) 2012 "Can the peptide neurotensin connect the dots and serve as a novel target for autism therapy?"
Autism One (The Westin Lombard Yorktown Center, Lombard, IL; May 25, 2012).

 

163) 2012 "Is there an intervention that combines anti-oxidant, anti-inflammatory, metal chelating,
mitochondrial protective, and neuroprotective effects?" Autism One (The Westin Lombard Yorktown Center,
Lombard, IL; May 27, 2012).

 

164) 2012 "Flavonoid combinations for cancer treatment." Emory University (Atlanta, GA; June 1, 2012).

 

165) 2012 "How genes and environment contribute to brain inflammation and symptoms." Family Café (Hilton,
Orlando, FL; June 15, 2012).

 

166) 2012 "Novel Treatment Approaches to Autism: How genes and environment contribute to brain
inflammation and symptoms." (West Palm Beach, FL;

 

167) 2012 "Novel Treatment Approaches to Autism: How genes and environment contribute to brain
inflammation and symptoms." Autism in Motion (Montreal, Canada; August 19, 2012).

 

168) 2012 "Neuro-inflammatory actions of human mast cells and comparison of the inhibitory effects of
ketotifen, cromolyn, quercetin and luteolin." (Cincinnati, OH; September 22, 2012).

 

170) 2012 "Activation of mast cells by the unique target mTOR leads to neurological symptoms inhibited by
luteolin." 18th Annual Conference of the Mastocytosis Society (Bellevue, WA; October 11-14, 2012).

 

171) 2012 "Activation of mast cells and neuroglia leads to brain inflammation inhibited by luteolin-implications
for treatment of Alzheimer 's disease and Autism." 8th Annual Conference of the European Nutraceutical
Association (Munich, Germany: November 3, 2012).

 

172) 2012 "Novel Treatment Approaches to Autism: How genes and environment contribute to brain
inflammation and symptoms." National Autism Association (St. Petersburg, FL; November 9-11, 2012).

 

173) 2013 "Neurotensin triggers brain inflammation blocked by liposomal luteolin-implications for the
pathogenesis and treatment of autism." Tufts Medical Center (Boston, MA;

 

174) 2013 "Innate Pathogens" causing focal brain inflammation." Autism One (Chicago, IL; May 23, 2013).
175) 2013 "A cell for all seasons: The mast cell." (West Roxbury VA Medical Center (West Roxbury, MA; June
3, 2013).

 

176) 2013 "2013 "New autism treatments target: Innate pathogens causing brain inflammation-Cutting down
autism by fighting brain immunity storms." ICare4Autism (New York, NY; June 6, 2013).

 

177) 2013 "New autism treatments target: Innate pathogens causing brain inflammation." Family Café
(Orlando, FL; June 7, 2013).

 

178) 2013 "Fibromyalgia neuro-inflammatory findings point to new treatments." Family Café (Orlando, FL;
June 7, 2013).

 

179) 2013 "Mast Cell Disorders and Neurological Symptoms." The Mastocytosis Society Annual Meeting
(Greenville, SC; Sep 26-29, 2013)

 

180) 2013 "Mast Cells, Coronary Hypersensitivity, Kounis syndrome and Takotsubo Cardiomyopathy"
The Mastocytosis Society Annual Meeting (Greenville, SC; Sep 26-29, 2013)

 

 

181) 2013 "Allergy" of the Brain" Medical Academy of Pediatric Special Needs Conference (MAPS)
Clinician's CME Training (Tampa, FL; Oct 3-5, 2013).

 

182) 2013 "New Autism Treatments Target Pro-Inflammatory "Innate Pathogens"", Autism Avenue 2013
Regional "Possibilities and Potential" Autism/Asperger Conference and Expo (Greensboro, NC; Oct 28,
2013).

 

183) 2013 "Could autism be related to brain inflammation?" Fourth Annual Meeting for Health Prevention
and Promotion-"Gazing at Children" (Syros, Greece; Nov 1-3, 2013).

 

184) 2013 "Is autism allergy of the brain?", National Autism Association (St. Petersburg, FL; Nov 14-17,
2013).

 

185) 2014 "Activated mast cells secrete "innate pathogens" causing focal brain inflammation inhibited by
luteolin." Molecular Basis of Brain Diseases (Miami, FL; Jan 26, 2014).
186) 2014 "New autism treatments target pro-inflammatory innate pathogens." SouthWestern "Across the
Spectrum" Autism/Asperger Conference (Atlanta, GA; March 13-14, 2014).

 

187) 2014 "The missing link in autoimmunity and autism" Ninth International Congress on Autoimmunity (Nice,
France; March 26-30, 2014).

 

188) 2014 "Autism and brain immunity storms." Autism One 2014 (Chicago, IL; May 23, 2014).

 

189) 2014 "Environmental and stress triggers of autism." IMMUNOe (Denver, CO; Aug 25, 2014)

 

190) 2014 "Coronary mast cell activation, myocardial infarction and POTS." 20th Annual Meeting of the
Mastocytosis Society (Rochester, MN; September 17, 2014).

 

191) 2014 "Synergistic activation of mast cells by the cytokine IL-33 and neuropeptide substance P."
20th Annual Meeting of the Mastocytosis Society (Rochester, MN; September 17, 2014).

 

192) 2014 "Implications of coronary mast cell activation." 20th Annual Meeting of the Mastocytosis Society
(Rochester, MN; September 17, 2014).

 

193) 2014 "Elevated serum stress hormone levels in children with autism predict response to treatment."
Autism Education Summit (Dallas, TX; October 17, 2014).

 

194) 2014 "Elevated serum stress hormones in children with autism and in "autistic" dogs." National Autism
Association (St. Petersburg, FL; November 15, 2014).

 

195) 2015 "Focal brain iammation in multiple sclerosis and autism." First PanHellenic Interscience Congress on
for pediatric Multiple Sclerosis (Athens, Greece; January 16-18, 2015).

 

196) 2015 "Brain inflammation and autism." (Melbourne, Australia, April 27, 2015).

 

197) 2015 "Brain fog and mastocytosis." Australasia Mastocytosis Society (Sydney, Australia; May 4, 2015).

 

198) 2015 "The musical vs. the behavioral brain in autism." The Boston Conservatory of Music (Boston, MA;
May 8-9, 2015).

 

199) 2015 "Methoxyluteolin inhibits human mast cells and reduces skin inflammation." Annual Congress of the
European Academy of Allergy and Clinical Immunology (Barcelona, Spain; June 6-10, 20150.

200) 2015 "An overview of mast cell disorders and inflammation." TMS San Francisco Bay Ara Meeting (San
Francisco, CA: July 26, 2015).

 

201) 2015 "Neurocognitive manifestations in mast cell disorders." TMS Annual Meeting (Washington, DS;
August 14-15, 2015).

 

202) 2015 "The cross-talk between the nervous system and the immune system." IgNS2015 (Washington, DC;
September 18-20, 20150.

 

203) 2015 "Objective biomarkers identify autism subgroup amenable to treatment." Autism Education Summit
(Dallas, TX; September 26-28, 2015).

 

204) National Autism Association (October 15, 2015; St. Pete, FL)

 

205) Autism Research Institute (December 5, 2015; Boston, MA, 2015)

 

206) Cyprus Pediatric Association (February 14, 2016; Nicosia, CY)

 

207) TARF Think Tank (February 19, 2016; Boston, MA)

 

208) NCIMS (February 27, 2016;Greenboro, NC)

 

209) TACA Massachusetts (March 12, 2016; Watertown MA)

 

210) 11th PanHellenic Conference on Allergy & Clinical Immunology (April 16, 2016; Athens, Greece)

 

211) TACA Webinar (April 25, 2016; 1 pm)

 

212) All Childrens Hospital (April 1, 2016; St. Pete, FL)

 

213) TACA Philadelphia (May 7, 2016; Philadelphia, PA)

 

214) Autism One (May 27, 2016; Chicago, IL)

 

215) Autism One Think Tank (May 28, 2016; Chicago, IL)

 

216) EAAACI (June 7-11, 2017; Vienna, Austria)

 

217) Old North State Medical Society (June 23-25, 2016; Raleigh, NC)

 

218) FASEB Summer Research Conference in the long-running Neuroimmunology series entitled "Translational
Neuroimmunology: From Mechanisms to Therapeutics" (July 24-29, 2016; Big Sky, MT)

 

219) 11th Annual USAAA World Autism and Asperger Conference (August 29, 2016; Louisville, KY)

 

220) MAPS Conference (September 9, 2016; Atlanta, GA)

 

221) The Mastocytosis Society (September 15-17, 2016; Orlando, FL)

 

222) Autism Education Summit (October 1, 2016; Dallas, TX)]

 

223) International College of Geriatric Psychoneuropharmacology (ICGP) (October 6-8, 2016; Athens, Greece)

 

224) TACA National Conference (October 22, 2016; Costa Mesa, CA)

 

225) ILADS Annual meeting (November 3, 2016; Philadelphia, PA)

 

226) Cyprus Pediatric Association Annual Meeting (November 17, 2016; Nicosia, Cyprus)

 

227) 1st International Conference on Autism (November 22, 2016; Paphos, Cyprus)

 

228) Cyprus Pediatric Association (February 14, 2016; Nicosia, CY)

 

229) TARF Think Tank (February 19, 2016; Boston, MA)

 

230) NCIMS (February 27, 2016; Greenboro, NC)

 

231) TACA Massachusetts (March 12, 2016; Watertown MA)

 

232) 11th PanHellenic Conference on Allergy & Clinical Immunology (April 16, 2016; Athens, Greece)

 

233) TACA Webinar (April 25, 2016; 1 pm)

 

234) Johns Hopkins-All Childrens Hospital Grand Rounds (April 1, 2016; St. Pete, FL)

 

235) TACA Philadelphia (May 7, 2016; Philadelphia, PA)

 

236) Autism One (May 27, 2016; Chicago, IL)

 

237) Autism One Think Tank (May 28, 2016; Chicago, IL)

 

238) EAAACI (June 7, 2017; Vienna, Austria)

 

239) FASEB Summer Research Conference in the long-running Neuroimmunology series entitled "Translational
Neuroimmunology: From Mechanisms to Therapeutics" (July 24-29, 2016; Big Sky, MT)

 

240) 11th Annual USAAA World Autism and Asperger Conference (August 29, 2016; Louisville, KY)

 

241) National Autism Association (September 10, 2016; New Orleans, LA)

 

242) The Mastocytosis Society (September 15-17, 2016; Orlando, FL)

 

243) Autism Education Summit (October 1, 2016; Dallas, TX)

 

244) International College of Geriatric Psychoneuropharmacology (ICGP) (October 6-8, 2016; Athens, Greece)

 

245) TACA National Conference (October 22, 2016; Costa Mesa, CA)

 

246) ILADS Annual meeting (November 3, 2016; Philadelphia, PA)

 

247) Cyprus Pediatric Association Annual Meeting (November 17, 2016; Nicosia, Cyprus)

 

248) 1st International Conference on Autism (November 22, 2016; Paphos, Cyprus)

 

249) Georgia TACA Association (February 24, 2017; Atlanta, GA)

 

250) Cyprus Autism Association (March 6-11, 2017; Nikosia, Cyprus)

 

251) Kansas Mastocytosis Society (April 30, 2017; Kansas City, KS)

 

252) Peru Autism Association (May 27-30, 2017; Lima, Peru)

 

253) Philadelphia TACA Association (May 12, 2017; State College, Philadelphia, PA

 

254) AutismOne (May 24-27, 2017; Colorado Springs, CO)

 

255) TACA (Talk About Curing Autism) National Conference (October 19, 2017; Costa Mesa, CA)

 

256) UK Autism Society (November 30, 2017; London, UK)

 

257) UK Mastocytosis Society (December 1, 2017; London, UK)

 

258) TARF Think Tank (February 18, 2017; Boston, MA)

 

259) Medical University of Plovdic (March 7, 2018; Plovdic, Bulgaria)

 

260) TACA Regional Conference (Philadelphia, PA; May 11, 2018)

 

261) Autism One (May 26, 2018; Chicago. IL)

 

262) International Conference on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
(June 1, 2018; London, UK)

 

263) European Congress on Lyme disease (July 15, 2018; Warsaw, Poland)

 

264) NIH Mast Cell Activation Syndrome Workshop (September 7, 2018; Rockville, MD)

 

265) Canadian Society of Allergy and Clinical Immunology (September 15-16, 2018; Halifax, Canada)

 

266) NorthEast TMS Support Group Meeting (August 18, 2018; Dover, NH)

 

267) Arizona TMS Support Group Meeting (November 3, 2018; Scottsdale, AZ)

 

268) Maryland TMS Support Group Meeting (December 8; Baltimore, MD)

 

269) Floating Hospital for Children-Ground Rounds (January 17; Boston, MA)

 

270) The Forum for Integrative Medicine (March 7-9, 2019; Seattle, WA)

 

271) Pediatric Neurology Grand Rounds-Tufts Medical Centeer (January 13, 2019)

 

272) TARF (February 21, 2019; Boston, MA)

 

273) TMS 25th Anniversary Conference (May 3, 2019; Palo Alto, CA)

 

274) American Initiative for Mast Cell Diseases sponsored by NIH (May 5, 2019; Stanford, CA)

 

275) International Conference on Fibromyalgia (May 12, 2019; Pescara, Italy)

 

276) MAPS Conference (September 24, 2019; Costa Mesa, CA)
97

 

277) ILADS Annual meeting (October 15, 2019; Boston, MA)

 

278) Inflammaging and Autoimmunity-A revolution in assessment and treatment (September 11-13, 2020; virtual)

 

279) TACA Annual Conference (October 1-31, 2020; virtual)
https://tacanow.org/conferences/virtual/

 

280) ISEAI Conference (October 2-4, 2020; virtual)
https://www.google.com/search?q=iseai+conference&oq=&aqs=chrome.0.69i59l8.23002029j0j15&sourceid=chrome&ie=UTF-8

 

281) WANP conference (October 8-12, 2020; vitrual)
https://wanp.org/event/wanps-annual-virtual-conference-connect-2020/

 

282) Medical University-Plovdiv Jubilee Scientific Conference on the occasion of its 75th Anniversary-Medicine of
the Future (October 29-31, 2020)
https://mu-plovdiv.bg/en/

 

283) International Conference on Medical Aspects of Genetics and Comorbidities in Autism (November 7-8;
virtual) https://fb.me/e/1xhzrnSv3

 

284) ACAM/AAPMD Conference (November 11-14, 2020; virtual)
https://www.acam.org/mpage/2020AAPMDHome

 

285) Forum for Integrative Medicine (March 5-7, 2021; virtual)
https://forumforintegrativemedicine.org/conference-schedule/

 

286) International Conference on Pediatrics and Neonatology (April 15-16, 2021; virtual)
__________________________________________
ACAM/AAPMD=American College for Advancementin Medicine/American Academy
of Pathological Medicine & Dentistry
EAAACI=European Academy of Allergy and Clinical Immunology
ILADS=International Lyme and Associated Diseases Society
ISEAI=International Society for Environmentally Acquired Illness
MAPS=Medical Academy of Pediatrics Special Needs
NCIMS=North Carolina Integrative Medical Society
TARF=The Autism Research Foundation
TMS=The Mastocytosis Society
98
TACA=The Autism Community in Acton (formerly Think About Curing Autism)
WANP=Washington Association of Naturopathic Physicians